Calidi Biotherapeutics, Inc. Earnings Per Share (Basic)
Calidi Biotherapeutics, Inc. (CLDI) reported Earnings Per Share (Basic) of -$2.94 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-13
- Calidi Biotherapeutics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$2.94.
- Calidi Biotherapeutics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.43.
- Calidi Biotherapeutics, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$569.50.
- Calidi Biotherapeutics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$2.21.
- Calidi Biotherapeutics, Inc. earnings per share, basic for fiscal 2025 was -$5.95.
- Calidi Biotherapeutics, Inc. earnings per share, basic for fiscal 2024 was -$35.70.
- Calidi Biotherapeutics, Inc. earnings per share, basic for fiscal 2023 was -$17.33, a 679.60% decline from fiscal 2022.
- Calidi Biotherapeutics, Inc. earnings per share, basic for fiscal 2022 was $2.99.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$2.94 10-Q · filed 2026-08-13 | -$8.31 10-Q · filed 2026-08-13 | -$3.23 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$7.99 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2026-03-31 | -$0.43 10-Q · filed 2026-05-14 | -$1.64 derived: net income ÷ weighted average shares · filed 2026-05-14 | -$5.61 derived: net income ÷ weighted average shares · filed 2026-05-14 | -$9.53 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2025-12-31 | -$569.50 derived: net income ÷ weighted average shares · filed 2026-03-27 | -$2473.69 derived: net income ÷ weighted average shares · filed 2026-03-27 | -$321.72 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$5.95 10-K · filed 2026-03-27 | ||||
| 2025-09-30 | -$2.21 10-Q · filed 2025-11-13 | -$178.87 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$6.40 10-Q · filed 2025-11-13 | -$41.95 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2025-06-30 | -$31.75 10-Q · filed 2026-08-13 | -$1.99 10-Q · filed 2025-08-08 | -$66.47 10-Q · filed 2026-08-13 | -$4.17 10-Q · filed 2025-08-08 | -$18.21 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$32.56 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||
| 2025-03-31 | -$2.21 10-Q · filed 2026-05-14 | -$0.18 10-Q · filed 2025-05-14 | -$8.04 derived: net income ÷ weighted average shares · filed 2026-05-14 | -$18.77 derived: net income ÷ weighted average shares · filed 2026-05-14 | -$38.20 derived: net income ÷ weighted average shares · filed 2026-05-14 | |||
| 2024-12-31 | -$3218.38 derived: net income ÷ weighted average shares · filed 2026-03-27 | -$9507.53 derived: net income ÷ weighted average shares · filed 2026-03-27 | -$21007.60 derived: net income ÷ weighted average shares · filed 2026-03-27 | -$35.70 10-K · filed 2026-03-27 | -$2.97 10-K · filed 2025-03-31 | |||
| 2024-09-30 | -$7.75 10-Q · filed 2025-11-13 | -$0.65 10-Q · filed 2024-11-12 | -$22795.62 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$42.40 10-Q · filed 2025-11-13 | -$3.54 10-Q · filed 2024-11-12 | -$31.32 derived: net income ÷ weighted average shares · filed 2025-11-13 | ||
| 2024-06-30 | -$16.75 10-Q · filed 2025-08-08 | -$1.40 10-Q · filed 2024-08-13 | -$39.61 10-Q · filed 2025-08-08 | -$3.30 10-Q · filed 2024-08-13 | -$19.25 derived: net income ÷ weighted average shares · filed 2025-08-08 | -$19.94 derived: net income ÷ weighted average shares · filed 2025-08-08 | ||
| 2024-03-31 | -$2.03 10-Q · filed 2025-05-14 | -$0.20 10-Q · filed 2024-05-14 | -$8.66 derived: net income ÷ weighted average shares · filed 2025-05-14 | -$10.49 derived: net income ÷ weighted average shares · filed 2025-05-14 | -$20.41 derived: net income ÷ weighted average shares · filed 2025-05-14 | |||
| 2023-12-31 | -$2.31 derived: net income ÷ weighted average shares · filed 2025-03-31 | -$4.11 derived: net income ÷ weighted average shares · filed 2025-03-31 | -$11.62 derived: net income ÷ weighted average shares · filed 2025-03-31 | -$17.33 10-K · filed 2025-03-31 | $1.73 10-K · filed 2024-03-15 | |||
| 2023-09-30 | -$1.41 10-Q · filed 2024-11-12 | -$0.14 10-Q · filed 2023-11-14 | -$12.58 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$19.80 10-Q · filed 2024-11-12 | -$1.98 10-Q · filed 2023-11-14 | -$4.21 derived: net income ÷ weighted average shares · filed 2024-11-12 | ||
| 2023-06-30 | -$14.24 10-Q · filed 2024-08-13 | -$21.75 10-Q · filed 2024-08-13 | -$3.07 derived: net income ÷ weighted average shares · filed 2024-08-13 | -$2.93 derived: net income ÷ weighted average shares · filed 2024-08-13 | ||||
| 2023-03-31 | -$0.75 10-Q · filed 2024-05-14 | -$0.70 derived: net income ÷ weighted average shares · filed 2024-05-14 | -$0.82 derived: net income ÷ weighted average shares · filed 2024-05-14 | |||||
| 2022-12-31 | -$0.39 derived: net income ÷ weighted average shares · filed 2024-03-15 | -$0.51 derived: net income ÷ weighted average shares · filed 2024-03-15 | $2.99 10-K · filed 2024-03-15 | |||||
| 2022-09-30 | -$0.63 10-Q · filed 2023-11-14 | -$2.08 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |